An observational study in Alzheimer Disease (AD), sponsored by IRCCS San Raffaele. Not yet recruiting at 1 site in Italy. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Alzheimer Disease by IRCCS San Raffaele — 8 open to participants now, 8 under way, none of them phase 3. Alzheimer Disease · IRCCS San Raffaele.
Among the 10 studies in Alzheimer Disease by IRCCS San Raffaele, this one is one of 4 that started in 2026, is one of 6 observational ones, and was the 5th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →8 of the 10 studies in Alzheimer Disease by IRCCS San Raffaele are open now, in 1 country. Recruiting first, the newest first:
IRCCS San Raffaele · Sites in Italy
Ages 18+ · Healthy volunteers
IRCCS San Raffaele · Sites in Italy
Ages 40+
IRCCS San Raffaele · Sites in Italy
Ages 55–80 · Healthy volunteers
IRCCS San Raffaele · Sites in Italy
Ages 50–85 · Healthy volunteers
IRCCS San Raffaele · Sites in Italy
Ages 40+
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 35 is below the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 113 across the 4 interventional studies, 80 across the 6 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
1 of the studies in Alzheimer Disease by IRCCS San Raffaele that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07431255IRCCS San RaffaeleGeneration of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Alzheimer Disease by IRCCS San Raffaele, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to test a new artificial intelligence (AI) method to create brain scan images without needing an extra scan. Currently, patients with memory problems often undergo two types of PET scans (Amyloid PET and FDG PET) to assess Alzheimer's disease. This study will use existing scan data from patients who already had both scans as part of their routine care.
The AI model will try to generate the FDG PET image using only the Amyloid PET scan and an MRI. If successful, this method could reduce radiation exposure, costs, and time for future patients by eliminating the need for a separate FDG injection and scan.
No new scans, injections, or procedures will be performed for this study. All data will be fully anonymized (personal information removed) before analysis. The study involves approximately 35 adult patients (age 50+) whose data were collected between January 2025 and December 2025 at IRCCS Ospedale San Raffaele in Milan, Italy.
This is a retrospective observational study conducted at IRCCS Ospedale San Raffaele, Milan, Italy. The study evaluates the accuracy of synthetic [18F]FDG PET images generated using a SwinUNETR deep learning model compared to native [18F]FDG PET images.
Study Population:
Adults (≥ 50 years) who underwent amyloid PET imaging (using Florbetaben or Flutemetamol), structural MRI, and [18F]FDG PET due to cognitive symptoms between January 2025 and December 2025. Approximately 35 patients meeting inclusion criteria will be included.
Methodology:
All imaging and clinical data were collected as part of routine diagnostic care; thus, no additional procedures, interventions, or interactions with patients are required for this study. All data are fully deidentified before analysis, consistent with GDPR and institutional data protection policy. The SwinUNETR model processes volumetric images to generate synthetic FDG PET images from early-phase amyloid PET and MRI inputs.
Objectives and Endpoints:
Primary Objective: To quantitatively and qualitatively assess the accuracy of synthetic FDG PET images compared with native FDG PET images.
Primary Endpoint: Pearson correlation coefficient and mean absolute error (MAE) of SUVR values obtained from native FDG PET and synthetic FDG PET in Alzheimer relevant areas of interest (precuneus, posterior cingulate, lateral temporal cortex, and frontal cortex).
Secondary Objective: To assess visual interpretability and clinical intuitiveness of synthetic FDG PET images by expert nuclear medicine physicians.
Secondary Endpoint: Inter-rater agreement (Cohen's kappa) among 2 blinded nuclear medicine physicians rating synthetic FDG scans as "clinically acceptable" or not.
Ethical Considerations:
Due to the retrospective and non-interventional nature of this study, no additional informed consent is required. A waiver of informed consent will be requested from the Ethics Committee. The image data will be fully anonymized in accordance with institutional policies.
Adults (≥50 years) with cognitive symptoms who underwent amyloid PET imaging (Florbetaben or Flutemetamol), structural MRI, and [18F]FDG PET at the Nuclear Medicine Department of IRCCS Ospedale San Raffaele, Milan, Italy, as part of routine diagnostic care between January 1, 2025 and December 31, 2025.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adults (≥50 years) with cognitive symptoms who underwent amyloid PET (Florbetaben or Flutemetamol), structural MRI, and \[18F\]FDG PET at IRCCS Ospedale San Raffaele between January 2025 and December 2025 as part of routine diagnostic care. All data are fully anonymized prior to analysis.
Quantitative Accuracy of Synthetic FDG PET Images (SUVR Correlation and MAE)
Pearson correlation coefficient and mean absolute error (MAE) of SUVR values obtained from native FDG PET and synthetic FDG PET in Alzheimer relevant areas of interest (precuneus, posterior cingulate, lateral temporal cortex, and frontal cortex).
Time frame: Retrospective analysis of imaging data acquired between January 1, 2025 and December 31, 2025
Regional SUVR Bias Between Synthetic and Native FDG Across Machine Types
Regional SUVR bias (mean difference ± standard deviation) between synthetic and native FDG across machine types and reconstructions used at Ospedale San Raffaele.
Time frame: Retrospective analysis of imaging data acquired between January 1, 2025 and December 31, 2025
Effect of Amyloid Status on Synthetic FDG Generation Accuracy
Stratified analysis of primary endpoint (SUVR correlation and MAE) by state of amyloid PET positivity (positive vs negative) based on established Centiloid or visual read criteria.
Time frame: Retrospective analysis of imaging data acquired between January 1, 2025 and December 31, 2025
Plan to share: Undecided — It is not yet decided whether individual participant data will be shared. The research team will consider data sharing requests on a case-by-case basis, subject to institutional approval and data use agreements. Anonymized imaging data (NIfTI format) and analysis scripts may be made available upon reasonable request to the Principal Investigator.
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.